Clinical safety and performance of the world’s thinnest-strut Evermine50 everolimus-eluting stent: a 24-month follow-up of the Evermine 50 EES – 1 study
The Evermine50 EES showed satisfactory primary clinical as well as angiographic outcomes, reaffirming the safety and performance of the world's thinnest-strut stent by exhibiting low rates of MACE at 24-month follow-up with an absence of any stent thrombosis and MI. Clinical Trials Registry-India (CTRI) number: CTRI/2017/02/007781.
Authors
- Dilip Kumar (ORCID: https://orcid.org/0000-0003-0495-7195)
- Deepak Davidson
- Sivaprasad Kunjukrishnapilla (ORCID: https://orcid.org/0000-0003-3162-1881)
- G. Manohar
- Ashokkumar Thakkar
- Jaspal Arneja
- Parneesh Arora
- Sanjeeb Roy (ORCID: https://orcid.org/0000-0002-5777-8695)
- Subhash Chandra (ORCID: https://orcid.org/0000-0002-1385-879X)
- Raghu R Thagachagere
Institutions
- Government Medical College (IN)
- Fortis Malar Hospital (IN)
- Caritas Hospital (IN)
- Sri Jayadeva Institute of Cardiovascular Sciences and Research (IN)
- Midas Multispeciality Hospital (IN)
- Fortis Hospital (IN)
- BLK Super Speciality Hospital (IN)
- Nethradhama Superspeciality Eye Hospital (IN)
- Meril Life Sciences (India) (IN)
Publication Details
- Journal
- AsiaIntervention
- Published
- 2024-09-01
- DOI
- https://doi.org/10.4244/aij-d-24-00009
- Citations
- 1
- Primary Topic
- Coronary Interventions and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.57